ALX ONCOLOGY HOLDINGS INC Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALX ONCOLOGY HOLDINGS INC stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $31.00K, a 106.67% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $15.00K, a 95.10% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $306.00K, a 9.47% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $338.00K, a 11.92% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC stock issued during period, value, employee stock purchase plan for fiscal 2025 was $24.00K, a 93.16% decline from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC stock issued during period, value, employee stock purchase plan for fiscal 2024 was $351.00K, a 32.89% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC stock issued during period, value, employee stock purchase plan for fiscal 2023 was $523.00K, a 55.65% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC stock issued during period, value, employee stock purchase plan for fiscal 2022 was $336.00K, a 66.34% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $31.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $24.00K 10-K · filed 2026-03-09 | |
| 2025-06-30 | $15.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $351.00K 10-K · filed 2026-03-09 | |
| 2024-06-30 | $306.00K 10-Q · filed 2025-11-07 | |
| 2023-12-31 | $523.00K 10-K · filed 2026-03-09 | |
| 2023-06-30 | $338.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $336.00K 10-K · filed 2025-03-06 | |
| 2022-06-30 | $302.00K 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $202.00K 10-K · filed 2024-03-07 |
| 2021-06-30 | $103.00K 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |